MX2020013206A - Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos. - Google Patents

Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos.

Info

Publication number
MX2020013206A
MX2020013206A MX2020013206A MX2020013206A MX2020013206A MX 2020013206 A MX2020013206 A MX 2020013206A MX 2020013206 A MX2020013206 A MX 2020013206A MX 2020013206 A MX2020013206 A MX 2020013206A MX 2020013206 A MX2020013206 A MX 2020013206A
Authority
MX
Mexico
Prior art keywords
fatty acid
gnrh
pharmaceutical composition
binding
same
Prior art date
Application number
MX2020013206A
Other languages
English (en)
Inventor
Dong Kyu Jin
Original Assignee
Novel Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novel Pharma Inc filed Critical Novel Pharma Inc
Publication of MX2020013206A publication Critical patent/MX2020013206A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un aspecto de la presente descripción se refiere a un nuevo derivado de hormona liberadora de gonadotropina (GnRH) conjugado con ácido graso de acción prolongada y una composición farmacéutica que lo contiene. Se espera que un derivado de GnRH de la presente invención contribuya en gran medida, a través de una excelente biodisponibilidad, un aumento de la vida media en sangre y efectos terapéuticos notablemente altos sobre la enfermedad dependiente de hormonas sexuales, a la reducción de la frecuencia y la dosis de dosificación del fármaco y similares en el tratamiento de enfermedades dependientes de las hormonas sexuales. En particular, el derivado de GnRH puede superar las desventajas de las preparaciones de liberación sostenida de GnRH existentes, que tienen los efectos secundarios de sensación residual y dolor en el lugar de la inyección.
MX2020013206A 2019-03-26 2019-03-26 Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos. MX2020013206A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2019/003527 WO2020196946A1 (ko) 2019-03-26 2019-03-26 지속형 지방산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
MX2020013206A true MX2020013206A (es) 2021-02-26

Family

ID=72611599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013206A MX2020013206A (es) 2019-03-26 2019-03-26 Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos.

Country Status (9)

Country Link
US (2) US20210030846A1 (es)
EP (1) EP3785734B1 (es)
JP (1) JP7066913B2 (es)
CN (1) CN112955181A (es)
AU (1) AU2019437315B2 (es)
CA (1) CA3102364A1 (es)
ES (1) ES2944511T3 (es)
MX (1) MX2020013206A (es)
WO (1) WO2020196946A1 (es)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06122611A (ja) * 1992-10-12 1994-05-06 Seiwa Kasei:Kk 化粧品用配合剤
US6664369B1 (en) * 1994-08-10 2003-12-16 Creighton University GnRH analogues with antitumour effects and pharmaceutical compositions thereof
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
JP2001139422A (ja) 1999-11-18 2001-05-22 Shiseido Co Ltd 乳化組成物
AU4738101A (en) 2000-03-17 2001-10-03 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US8552054B2 (en) * 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
US6958142B2 (en) 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
WO2004012712A1 (en) * 2002-08-02 2004-02-12 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders, contraception, and hormone replacement
US6960337B2 (en) 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
AU2002368261A1 (en) 2002-10-02 2004-04-23 Yeda Research And Development Co. Ltd. Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
US20060003008A1 (en) * 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
TW200529890A (en) 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US20080027003A1 (en) 2004-05-27 2008-01-31 Curepeptide Ltd. Peptides Useful for Treating Gnrh Associated Diseases
CN101563068B (zh) 2006-12-18 2013-03-20 武田药品工业株式会社 缓释组合物和其制备方法
PL2331075T3 (pl) 2008-08-29 2016-04-29 Genzyme Corp Formulacje peptydowe o kontrolowanym uwalnianiu
JP5674089B2 (ja) 2010-03-25 2015-02-25 日油株式会社 毛髪化粧料
BR112013024784A2 (pt) 2011-04-07 2018-09-25 Univ Leland Stanford Junior análogos de peptídeos de ação prolongada
MX357841B (es) 2012-02-28 2018-07-26 Tiumbio Co Ltd Antagonistas de los receptores de la hormona liberadora de gonadotropina, método para la preparación de éstos y composición farmacéutica que los contienen.
JP6434408B2 (ja) * 2012-08-24 2018-12-05 インテグアールエックス セラピューティクス， エルエルシーＩｎｔｅｇｕｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ 治療剤の経皮送達を増強するための化学組成物および方法
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
WO2016102683A1 (en) * 2014-12-23 2016-06-30 Camurus Ab Controlled-release formulations
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AU2018338924B2 (en) 2017-09-27 2020-05-21 Novel Pharma Inc. Long-acting palmitic acid-conjugated GnRH derivative, and pharmaceutical composition containing same

Also Published As

Publication number Publication date
CA3102364A1 (en) 2020-10-01
US11975048B2 (en) 2024-05-07
CN112955181A (zh) 2021-06-11
US20220054593A1 (en) 2022-02-24
ES2944511T3 (es) 2023-06-21
JP2021524496A (ja) 2021-09-13
US20210030846A1 (en) 2021-02-04
EP3785734A1 (en) 2021-03-03
AU2019437315B2 (en) 2022-10-06
AU2019437315A1 (en) 2020-12-03
EP3785734B1 (en) 2023-04-12
WO2020196946A1 (ko) 2020-10-01
EP3785734A4 (en) 2021-12-29
JP7066913B2 (ja) 2022-05-13

Similar Documents

Publication Publication Date Title
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MX2011013150A (es) Composicion farmaceutica para uso en oftalmologia medica y veterinaria.
MX2011011478A (es) Composiciones de tabletas que se desintegran oralmente que comprenden combinaciones de farmacos en dosis alta y baja.
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
MX2020002247A (es) Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene.
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
Avanti et al. A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate
MX2021000127A (es) Formulaciones de un inhibidor de axl/mer.
AR120290A1 (es) Una forma de dosificación parenteral estable de acetato de cetrorelix
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2020013206A (es) Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos.
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
EA201992685A1 (ru) Раствор леводопы для инфузий
RU2015120055A (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
ZA202308033B (en) Method and pharmaceutical combination for preventing cancer recurrence
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
EA201400484A1 (ru) Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей
MY191983A (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
MX2021014349A (es) Metodo para tratar cancer con una forma de dosificacion oral de un inhibidor de receptores de estrogeno-alfa.
TW200633722A (en) Complexes made using low solubility drugs